{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:44:03Z","timestamp":1792511043699,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 diabetes mellitus (T2DM) is closely linked to obesity and carries a high risk of metabolic complications. While GLP-1 receptor agonists like dulaglutide improve blood sugar and support modest weight loss, many patients do not reach their treatment goals. Mazdutide, a dual GLP-1 and glucagon receptor agonist, may offer stronger metabolic benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of mazdutide versus dulaglutide in adults with T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed randomized controlled trials comparing mazdutide and dulaglutide. Primary outcomes included changes in HbA1c, body weight, and achievement of glycemic and weight-loss targets. Safety outcomes included treatment-emergent adverse events. Data were pooled using random-effects models, and evidence certainty was assessed using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three trials met inclusion criteria. Mazdutide led to greater reductions in HbA1c (\u2212\u20090.25%) and body weight (\u2212\u20092.97\u00a0kg) compared with dulaglutide. Patients were more likely to achieve HbA1c\u2009&lt;\u20097.0%, \u2265\u20095% weight loss, and the combined target of \u2265\u20095% weight loss with HbA1c\u2009&lt;\u20097.0%. Fasting plasma glucose was numerically but not significantly improved. Mazdutide was associated with higher rates of gastrointestinal side effects and decreased appetite, with a non-significant numerical increase in hypoglycemia, while serious adverse events and discontinuations were similar between treatments. Glycemic and major weight outcomes were supported by high-certainty evidence; most safety outcomes were moderate-certainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mazdutide, based on evidence from three RCTs, provides preliminary evidence of meaningful improvements in blood sugar control and weight loss compared with dulaglutide, though with an increased risk of mostly manageable gastrointestinal effects; given the limited number of trials, these findings should be considered preliminary and supporting its potential role as a promising dual-action therapy for T2DM management, pending confirmation in larger, longer-term trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-026-02248-3","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:15:04Z","timestamp":1784880904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"18","author":[{"given":"Muhammad","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Tayyab","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain Ul Abideen","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Mussawir","family":"Khuhro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Bhagia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasibullah","family":"Aminpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2248_CR1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2021","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021.","edition":"10"},{"key":"2248_CR2","volume-title":"Obesity and overweight","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Obesity and overweight. Geneva: World Health Organization; 2022."},{"key":"2248_CR3","doi-asserted-by":"crossref","unstructured":"Abarca-G\u00f3mez L, Abdeen Z, Hamid Z, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390:2627\u201342.","DOI":"10.1016\/S0140-6736(17)32129-3"},{"issue":"Suppl 1","key":"2248_CR4","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: standards of care in diabetes\u20142024. Diabetes Care. 2024;47(Suppl 1):S20\u201342.","journal-title":"Diabetes Care"},{"key":"2248_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.mcna.2004.04.013","volume":"88","author":"RA DeFronzo","year":"2004","unstructured":"DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787\u2013835.","journal-title":"Med Clin North Am"},{"key":"2248_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global etiology and epidemiology of type 2 diabetes. Nat Rev Endocrinol. 2018;14:88\u201398.","journal-title":"Nat Rev Endocrinol"},{"key":"2248_CR7","unstructured":"American Diabetes Association Professional Practice Committee. Introduction and methodology: standards of care in diabetes\u20142025. Diabetes Care. 2025;48(Suppl 1):S1\u2013S5."},{"key":"2248_CR8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control and vascular outcomes. Lancet. 1998;352:837\u201353.","journal-title":"Lancet"},{"key":"2248_CR9","first-page":"18904","volume":"5","author":"F Sun","year":"2015","unstructured":"Sun F, et al. GLP-1 receptor agonists in type 2 diabetes: meta-analysis. Sci Rep. 2015;5:18904.","journal-title":"Sci Rep"},{"key":"2248_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, et al. Cardiovascular outcomes with GLP-1 receptor agonists. Lancet Diabetes Endocrinol. 2019;7:776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2248_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and cardiovascular outcomes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"2248_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70643","author":"MH Azam","year":"2026","unstructured":"Azam MH, Azam MH, Azam K, Azam MA, Afridi MK, Waqas SA, et al. Efficacy and safety of mazdutide in managing overweight and obesity among non-diabetic adults: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2026. https:\/\/doi.org\/10.1111\/dom.70643.","journal-title":"Diabetes Obes Metab"},{"key":"2248_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd.2018.165","volume":"17","author":"TD M\u00fcller","year":"2018","unstructured":"M\u00fcller TD, et al. Glucagon-based multi-agonism for metabolic disease. Nat Rev Drug Discov. 2018;17:698\u2013714.","journal-title":"Nat Rev Drug Discov"},{"key":"2248_CR14","doi-asserted-by":"crossref","unstructured":"Zhang B, Cheng Z, Chen J, Zhang X, Liu D, Jiang H et al. Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care. 2023;47(1):160-8. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37943529\/\u2060","DOI":"10.2337\/dc23-1287"},{"key":"2248_CR15","unstructured":"Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2025 Dec 17. Available from: https:\/\/www.nature.com\/articles\/s41586-025-10031-z\u2060"},{"key":"2248_CR16","doi-asserted-by":"publisher","first-page":"108150","DOI":"10.1016\/j.cct.2025.108150","volume":"160","author":"Y Luo","year":"2025","unstructured":"Luo Y, Jiang H, Shi B, Cai H, Wang H, Li S, et al. Mazdutide versus semaglutide for the treatment of type 2 diabetes and obesity: rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemp Clin Trials. 2025;160:108150. https:\/\/doi.org\/10.1016\/j.cct.2025.108150.","journal-title":"Contemp Clin Trials"},{"key":"2248_CR17","unstructured":"Azam MH, Azam MT, Azam MH, Shahid ZUA, Khan S, Khuhro MM, Bhagia S. Efficacy and safety of mazdutide versus dulaglutide in adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. PROSPERO 2026 CRD420261342203. Available from: https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261342203\u2060"},{"key":"2248_CR18","unstructured":"The Cochrane Collaboration. Review Manager (RevMan) [computer software]. Version 5.4. Cochrane Collaboration. 2020. Available from: https:\/\/training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/revman\u2060"},{"key":"2248_CR19","doi-asserted-by":"publisher","unstructured":"Higgins PT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58. Available from: https:\/\/doi.org\/10.1002\/sim.1186\u2060","DOI":"10.1002\/sim.1186\u2060"},{"key":"2248_CR20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.ad","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.ad.","journal-title":"BMJ"},{"key":"2248_CR21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"2248_CR22","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol Metab. 2021;46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102.","journal-title":"Mol Metab"},{"key":"2248_CR23","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1111\/dom.15693","volume":"26","author":"JB Winther","year":"2024","unstructured":"Winther JB, Holst JJ. Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity. Diabetes Obes Metab. 2024;26:3501\u201312. https:\/\/doi.org\/10.1111\/dom.15693.","journal-title":"Diabetes Obes Metab"},{"key":"2248_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12020-024-03857-6","volume":"86","author":"B Deng","year":"2024","unstructured":"Deng B, Ruan T, Lu W, Ying J, Li S, Zhou R, Mu D. Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2024;86:15\u201327. https:\/\/doi.org\/10.1007\/s12020-024-03857-6.","journal-title":"Endocrine"},{"key":"2248_CR25","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/dmrr.2810","volume":"32","author":"J Jendle","year":"2016","unstructured":"Jendle J, Grunberger G, Blevins T, et al. Efficacy and safety of dulaglutide in type 2 diabetes: review of the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32:776\u201390. https:\/\/doi.org\/10.1002\/dmrr.2810.","journal-title":"Diabetes Metab Res Rev"},{"key":"2248_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40259-015-0143-4","volume":"29","author":"CB Burness","year":"2015","unstructured":"Burness CB, Scott LJ. Dulaglutide: a review in type 2 diabetes. BioDrugs. 2015;29:407\u201318. https:\/\/doi.org\/10.1007\/s40259-015-0143-4.","journal-title":"BioDrugs"},{"key":"2248_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"key":"2248_CR28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/dom.12736","volume":"18","author":"TS Bailey","year":"2016","unstructured":"Bailey TS, Tak\u00e1cs R, Tinahones FJ, et al. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH). Diabetes Obes Metab. 2016;18:1191\u20138. https:\/\/doi.org\/10.1111\/dom.12736.","journal-title":"Diabetes Obes Metab"},{"key":"2248_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/dom.13086","volume":"20","author":"B Gallwitz","year":"2018","unstructured":"Gallwitz B, Dagogo-Jack S, Thieu V, et al. Effect of once-weekly dulaglutide on HbA1c and fasting blood glucose in patient subpopulations. Diabetes Obes Metab. 2018;20:409\u201318. https:\/\/doi.org\/10.1111\/dom.13086.","journal-title":"Diabetes Obes Metab"},{"key":"2248_CR30","doi-asserted-by":"publisher","first-page":"104996","DOI":"10.1016\/j.phrs.2020.104996","volume":"159","author":"CC Berra","year":"2020","unstructured":"Berra CC, Resi V, Mirani M, et al. Clinical efficacy and predictors of response to dulaglutide in type 2 diabetes. Pharmacol Res. 2020;159:104996. https:\/\/doi.org\/10.1016\/j.phrs.2020.104996.","journal-title":"Pharmacol Res"},{"key":"2248_CR31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","volume":"67","author":"M Bl\u00fcher","year":"2024","unstructured":"Bl\u00fcher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide. Diabetologia. 2024;67:470\u201382. https:\/\/doi.org\/10.1007\/s00125-023-06053-9.","journal-title":"Diabetologia"},{"key":"2248_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide for people with type 2 diabetes: a phase 2 trial. Lancet. 2023;402:529\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X.","journal-title":"Lancet"},{"key":"2248_CR33","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1017\/S2045796021000664","volume":"30","author":"P Cuijpers","year":"2021","unstructured":"Cuijpers P, Griffin JW, Furukawa TA. The lack of statistical power of subgroup analyses in meta-analyses. Epidemiol Psychiatr Sci. 2021;30:e78. https:\/\/doi.org\/10.1017\/S2045796021000664.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2248_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"DG Altman","year":"2003","unstructured":"Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219. https:\/\/doi.org\/10.1136\/bmj.326.7382.219.","journal-title":"BMJ"},{"key":"2248_CR35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea with GLP-1 receptor agonists: systematic analysis. Diabetes Obes Metab. 2017;19:336\u201347. https:\/\/doi.org\/10.1111\/dom.12824.","journal-title":"Diabetes Obes Metab"},{"key":"2248_CR36","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/phar.1507","volume":"34","author":"JM Trujillo","year":"2014","unstructured":"Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014;34:1174\u201386. https:\/\/doi.org\/10.1002\/phar.1507.","journal-title":"Pharmacotherapy"},{"key":"2248_CR37","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s13300-020-00869-z","volume":"11","author":"L Guo","year":"2020","unstructured":"Guo L, Zhang B, Hou J, et al. Evaluation of gastrointestinal adverse events with once-weekly dulaglutide in Chinese patients: pooled analysis. Diabetes Ther. 2020;11:1821\u201333. https:\/\/doi.org\/10.1007\/s13300-020-00869-z.","journal-title":"Diabetes Ther"},{"key":"2248_CR38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2337\/dc16-0984","volume":"40","author":"MA Nauck","year":"2017","unstructured":"Nauck MA, Frossard JL, Barkin JS, et al. Assessment of pancreas safety in the development program of once-weekly dulaglutide. Diabetes Care. 2017;40:647\u201354. https:\/\/doi.org\/10.2337\/dc16-0984.","journal-title":"Diabetes Care"},{"key":"2248_CR39","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1007\/s13300-021-01139-2","volume":"12","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Zhu J, Wu H, et al. Pancreatic safety of once-weekly dulaglutide in Chinese patients: subgroup analysis. Diabetes Ther. 2021;12:2677\u201390. https:\/\/doi.org\/10.1007\/s13300-021-01139-2.","journal-title":"Diabetes Ther"},{"key":"2248_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-016-0490-6","volume":"16","author":"M Lorenz","year":"2017","unstructured":"Lorenz M, Lawson F, Owens D, et al. Differential effects of GLP-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16:6. https:\/\/doi.org\/10.1186\/s12933-016-0490-6.","journal-title":"Cardiovasc Diabetol"},{"key":"2248_CR41","doi-asserted-by":"publisher","first-page":"101552","DOI":"10.1016\/j.diabet.2024.101552","volume":"50","author":"C Samhani","year":"2024","unstructured":"Samhani C, Guerci B, Larose C. Cutaneous hypersensitivity reaction to dulaglutide: a case report. Diabetes Metab. 2024;50:101552. https:\/\/doi.org\/10.1016\/j.diabet.2024.101552.","journal-title":"Diabetes Metab"},{"key":"2248_CR42","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.2105\/AJPH.2007.124537","volume":"98","author":"JA Berlin","year":"2008","unstructured":"Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations beyond phase 3. Am J Public Health. 2008;98:1366\u201371. https:\/\/doi.org\/10.2105\/AJPH.2007.124537.","journal-title":"Am J Public Health"},{"issue":"1","key":"2248_CR43","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1038\/s41467-022-31328-x","volume":"13","author":"H Jiang","year":"2022","unstructured":"Jiang H, Pang S, Zhang Y, Yu T, Liu M, Deng H, Li L, Feng L, Song B, Han-Zhang H, Ma Q, Qian L, Yang W. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022;13(1):3613. https:\/\/doi.org\/10.1038\/s41467-022-31328-x.","journal-title":"Nat Commun"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02248-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02248-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02248-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:01:55Z","timestamp":1792508515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02248-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2248"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02248-3","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human ethics approval and consent to participate were not required for this study because it is a systematic review and meta-analysis based on previously published studies. No primary data involving human participants were collected.","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"219"}}